Anti-Human IL‑23 p19 Recombinant Antibody (SAA0392) (HV466207)

Name: Anti-Human IL‑23 p19 Recombinant Antibody (SAA0392)
Brand: abinScience
SKU: HV466207
Price: 196 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

50ug
100ug

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	HV466207
Reactivité des espèces	Human
Applications	ELISA, FCM, WB
Espèce hôte	Human
Clonalité	Monoclonal
Isotype	IgG4, kappa
ID de clone	SAA0392
Applications testées	WB, FCM
Cible	IL-23 subunit alpha, IL-23-A, IL-23p19, IL23A, Interleukin-23 subunit alpha, Interleukin-23 subunit p19, SGRF
Niveau d'endotoxines	< 10 EU/mg
Pureté	>95% as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	Q9NPF7
Forme	Liquid
Tampon de stockage	0.01M PBS pH 7.4. Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Contexte	Interleukin-23 subunit alpha (IL23A) is a ~20 kDa protein. Associates with IL12B to form the pro-inflammatory cytokine IL-23 that plays different roles in innate and adaptive immunity. Released by antigen-presenting cells such as dendritic cells or macrophages, binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R to activate JAK2 and TYK2 which then phosphorylate the receptor to form a docking site leading to the phosphorylation of STAT3 and STAT4. This process leads to activation of several pathways including p38 MAPK or NF-kappa-B and promotes the production of pro-inflammatory cytokines such as interleukin-17A/IL17A. In turn, participates in the early and effective intracellular bacterial clearance. Promotes the expansion and survival of T-helper 17 cells, a CD4-positive helper T-cell subset that produces IL-17, as well as other IL-17-producing cells. IL23A is the therapeutic target of guselkumab (Tremfya). 1. Oppmann, B. et al. (2000) Immunity 13, 715-25. PMID: 11114383 2. Bloch, Y. et al. (2018) Immunity 48, 45-58.e6. PMID: 29287995 3. Sun, R. et al. (2020) Cellular and molecular gastroenterology and hepatology 10, 673-697. PMID: 32474165 4. Glassman, CR. et al. (2021) Cell 184, 983-999.e24. PMID: 33606986 5. Parham, C. et al. (2002) Journal of immunology (Baltimore, Md. : 1950) 168, 5699-708. PMID: 12023369 6. Wilson, NJ. et al. (2007) Nature immunology 8, 950-7. PMID: 17676044
Note	For research use only.

Images

Bioactivity

SEC-HPLC detection for Anti-Human IL23A Antibody (ABS0131).
Flow Cytometry

Flow-cytometry using anti-human IL23A antibody.IL23A Transfected CHO cells were stained with an irrelevant antibody (Blue Histogram) or an anti-human IL23A antibody monoclonal antibody (Catalog # HV466207 ,Green Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a FITC conjugated goat anti-human antibody (Catalog # HF690414) and cells analysed on a NovoCyte Flow Cytometer.
Western blot

Western blot analysis was performed using anti-IL23A monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human IL23A (Catalog No: HV466011)
Lane 2: negative control